Medical Advocates
Atazanavir (Reyataz)
 
Conference Citations

XX International AIDS Conference
7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention
XIX International AIDS Conference
XVIII International AIDS Conference
5th IAS Conference
Ninth Int. Congress on Drug Therapy in HIV Infection
XVII International AIDS Conference

 Conference Archives

  
Atazanavir Main Page Main New/Newsworthy Home Page      
Last updated:  December 06, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
XX International AIDS Conference
 
7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention
 
  • Pharmacokinetic (PK) interactions between boceprevir (BOC) and atazanavir (ATV/r) or raltegravir (RAL) in HIV/HCV-co-infected patients (pts). ANRS HC27 study
     R. Garraffo, ANRS HC 27 BOCEPRE VIH Study Group
     Abstract
  • Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacy and preterm delivery rates
    M. Perry, K. Conway, S. Flanagan, et al
     Abstract
XIX International AIDS Conference
 
  • Atazanavir pharmacokinetics and efficacy and safety outcomes by sex in AIDS Clinical Trials Group Study 5202 (A5202)
    C. Venuto, K. Mollan, Q. Ma, et al
    Abstract
  • The incidence of the hypertriglyceridemic waist phenotype in a randomized prospective comparison between atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir (LPV/r) each in combination with tenofovir DF/emtricitabine (TDF/FTC) in antiretroviral naive HIV
    G. Moyle, W. Hu2, R. Wang2 V. Wirtz, et al
    Abstract
  • Complicated atazanavir-associated cholelithiasis: a report of eight documented cases among 11 cases
    Y. Poinsignon, F. Borsa-Lebas, H. Jantzem, et al
     Abstract
  • Economic and quality adjusted life year (QALY) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral (ARV) naïve Colombian HIV patients in 2011
     K. Simpson, R. Baran, S. Kirbach, et al
    Abstract
  • A WEEK-IN-REVIEW FEATURED REPORT
    Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing boosted atazanavir
    J.-M. Lacombe, S. Abgrall,,J. Ghosn, et al
    Abstract
  • Analysis of efficacy by baseline viral load: phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir
    DF (quad) versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive subjects: week 48 res
    E. DeJesu J. Rockstroh, K. Henry, et al
     Abstract
  • Treatment simplification to atazanavir/ritonavir plus lamivudine QD in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control:
    96 weeks follow-up of a pilot study (Atazanavir and Lamivudine Simplification Study, ATLAS)
    M. Fabbiani, M. Colafigli, S. Farina, et al
    Abstract
6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • POSTER
    Methods for reducing the costs of antiretroviral treatments (ART) without reducing effectiveness
     R.M. Grimes, T.A. Shenouda  
     Poster     Abstract
  • POSTER
    Factors associated with a good HAART response in HIV patients
    D. Perez, J. Perez
     Poster         Abstract
  • POSTER
    Late HAART initiation in Latin America and the Caribbean: late testers and late presenters
    B. Crabtree-Ramírez, Y. Caro-Vega, B. Shepherd, et al
     Poster    Abstract
  • POSTER
         Factors associated with HAART adherence in adolescents and youth living with HIV in Argentina
    M.V. Zalazar, M. Vazquez, M. Rojo, et al
    Poster    Abstract
  • Cumulative viremia under HAART predicts long-term clinical outcomes
    V.D. Lima, J. Sierra-Madero, Z. Wu, et al
     Abstract
  • Characterizing nonadherence among urban HIV-infected adolescents
    R. Lagrange, M. Lewis, A. Vyas, et al
     Abstract
  • The problematic of adolescent antiretroviral treatment adherence
    Z.-K. Alice, K. Sonia, C. Bernadette
  • Bridging the gap of poor adherence of adolescent on antiretroviral drugs (ARVS) in Baylor College of Medicine
    Children´s Foundation, Uganda
    J. Paalo, L. Opendi, S. Okoboi, et al
     Abstract
  • Cumulative viremia under HAART predicts long-term clinical outcomes
    V.D. Lima, J. Sierra-Madero, Z. Wu, et al
  • Is the magic bullet already too late: a systematic review of the prevalence of transmitted HIV drug
    resistance in treatment-naïve patients, South Africa
    K. Velen, J. Klausner
    Abstract
  • Long term follow-up of antiretroviral therapy for HIV-2 infection in Senegal, West Africa
    S.N. Ba, N.M. Dia Badiane, M. Toure. et al
     Abstract
    •
18th CROI
 
XVIII International AIDS Conference
 
  • POSTER
         Virological response to atazanavir, ritonavir and tenofovir/emtricitabine: relation to individual
    pharmacokinetic parameters and adherence measured by medication events monitoring system
    (MEMS) in naïve HIV-infected patients (ANRS134 trial)
    C. Goujard, A. Barrail-Tran, X. Duval, et al
    PDF Poster         Abstract
  • POSTER
         METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted
    protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of
    darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks
    J. Aberg, T. Overton, S. Gupta, et al
    PDF Poster         Abstract
  • POSTER
         Long-term efficacy and safety of a switch to unboosted atazanavir (ATV) in well controlled HIV-1
    infected patients, results of the NEAT Unboosted Atazanavir Cohort
    A. Rachline, C. Torti, J. Medrano, et al
    PDF Poster         Abstract
  • Safety and efficacy of treatment simplification to atazanavir/ritonavir plus lamivudine in patients on
    two NRTIs plus atazanavir/ritonavir with optimal virologic control: 24 weeks results from a pilot study
    (atazanavir and lamivudine simplification study, ATLAS)
     A. De Luca, L. Bracciale, M. Doino, et al
    Abstract
  • Therapeutic drug monitoring (TDM) of different doses of atazanavir (ATV)/ ritonavir (RTV) when
    co-administered with the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or
    nevirapine
     J. Toy, C. Olatunbosun, M. Harris, et al
     Abstract
5th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • CONFERENCE POSTER
         The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily
    given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182
    F. Conradie, C. Zorilla, D. Josipovic, et al
    PDF Poster          Abstract
  • CONFERENCE POSTER
         Long-term efficacy and safety of a switch to unboosted atazanavir-based regimens among HIV-infected
    patients with suppression of viral replication: a retrospective cohort study
    J. Pavie, A. Rachline, R. Porcher, et al
    PDF Poster         Abstract
  • CONFERENCE POSTER
         Phenotypic susceptibility and drug resistance profile of HIV-1 B, C and AG clones selected with
    atazanavir, lopinavir and nelfinavir
    I. Lisovsky, J.L. Martinez Cajas, M. Oliveira
    PDF Poster     Abstract
  • Efficacy and safety of atazanavir/r vs. lopinavir/r in treatment-naïve patients with advanced disease:
    CASTLE study 96-week results
    J. Uy, R. Yang, V. Wirtz,  et al
     Abstract
  • Efficacy, safety and pharmacokinetic profile of a simple antiretroviral regimen containing unboosted
    atazanavir, didanosine EC and lamivudine in naïve HIV-1 infected patients in Senegal (REYADAK
    study-IMEA-031)
    R. Landman, M.-B. Diallo, G. Peytavin, et al
     Abstract
  • Efficacy, safety and pharmacokinetic profile of a simple antiretroviral regimen containing unboosted
    atazanavir, didanosine EC and lamivudine in naïve HIV-1 infected patients in Senegal (REYADAK
    study-IMEA-031)
    R. Landman, M.-B. Diallo, G. Peytavin, et al
     Abstract
  • Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each
    in combination with abacavir/lamivudine (ABC/3TC), after initial supression with ABC/3TC +
    ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial
    K. Squires, B. Young, E. DeJesus, et a
     Abstract
  • A short trial of unboosted atazanavir in patients with high trough levels on ritonavir-boosted
    atazanavir to select candidates for unboosted maintenance therapy
    S. Guillemi, J. Toy, M. Harris, et al
     Abstract
16th CROI
 
Ninth International Congress on Drug Therapy in HIV Infection
 
  • Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with
    VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136
     JF Delfraissy, S Moreno, J Sanz-Moreno,et al
    PDF Abstract
  • Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r
    and lopinavir/r in the CASTLE study
     Uy J, Yang R, Thiry A, Absalon J, et al
    Abstract
  • L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
     Vachta J, Wiesmann F, Braun P, et al
    Abstract
  • Protease inhibitor atazanavir induces leukocyte-endothelial cell interactions in the microvasculature
     Andrade MM, De Pablo-Bernal C, Esplugues JV, et al
    Abstract
  • Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing
    HAART: ATAZIP 96-week results
    Mallolas J, Podzamczer D, Domingo P, et al
     Abstract
  • Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
     Absalon J, Thal G, Thiry A, Yang R, et al
    Abstract
  • Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patients
     Avihingsanon A, van der Lugt J, Kerr S, et al
    Abstract
  • Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response
    and hyperbilirubinemia
     Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al
    Abstract
  • Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction
     Giola M, Cusato M, Villani P, et al
    Abstract
XVII International AIDS Conference
 
  • Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
         C. Ferreira, G. Morau, G. Peytavin, et al
    Abstract
  • Fasting increases serum bilirubin concentrations in patients on atazanavir
         G. Lopardo , L. Espinola , E. Bissio, et al
     Abstract
  • Pharmacokinetic drug-drug interaction between IDX899 and Atazanavir
         X.-J. Zhou , K. Pietropaolo, B. Belanger, et al
     Abstract
  • Long term surveillance of severe adverse events in HIV-1 infected patients treated with atazanavir: results from the
    SCOLTA project
         R. Giuntini, C. Martinelli, E. Ricci, et al
     Abstract
  • Increase in bilirubin in HIV/HCV coinfected patients treated with atazanavir following initiation of peginterferon plus
    ribavirin
         S. Rodriguez-Novoa, J. Morello, M. Gonzalez, et al
     Abstract
  • Effect of simplification from protease inhibitors (PIs) to boosted atazanavir (ATV/r)-based regimens in real-life conditions:
    final 1 year results of GESIDA 44/04 SIMPATAZ study
         R. Rubio, J. Carmen, V. Asensi, et al
     Abstract
  • Efficiency, safety and plasma concentrations of atazanavir, ritonavir and nevirapine in HIV-1 infected patients receiving
    ATV/r + NVP once daily regimen
         M. Kirstette, O. Taulera, M. Bary, et al
     Abstract
  • Resistance to unboosted atazanavir among HIV-1 subtype A/E infected patients who are naïve to protease inhibitor
         S. Sungkanuparph, W. Manosuth, S. Wiboonchutikul, et al
  • Efficacy and safety by racial group in ARV-naive subjects treated with atazanavir/ritonavir or lopinavir/ritonavir:
    48 week results for the CASTLE study (AI424138)
         D. McGrath, J. Uy, R. Yang, et al
     Abstract
  • Pharmacokinetics and clinical outcomes with Atazanavir 300 mg QD/ritonavir 100 mg (ATV/r) QD + ZDV/3TC
    during the 3rd trimester of pregnancy in HIV+ women: interim results from BMS AI424182
         T. Eley, E. Vandeloise, M. Child,  et al
         Abstract
  • The effects of aging on Atazanavir plasma concentrations in HIV-infected patients treated with ATV/r (300/100 mg qd)
    containing regimen
         A. Rahal, D. Descamps D. Manene, et al
         Abstract
  • Impact of baseline resistance on virologic efficacy of dual-boosted once-daily (QD) atazanavir, fosamprenavir, and
    ritonavir (ATV/FPV/RTV)
         U.F. Bredeek, B. Williams, R. Feldman, T. Lancaster
         Abstract
  • Health related quality of life (HRQoL) improvement in antiretroviral (ARV) naïve HIV-infected patients on ritonavir with
    atazanavir or lopinavir regimens: week 24 results from AI424138
         J. Su, J. Absalon, M. Mancini, et al
         Abstract
  • Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
         C. Ferreira, G. Morau, G. Peytavin,  et al
    Abstract
 

Atazanavir Main Page Main New/Newsworthy Home Page